Author

Lauren N. Adkins

Observed name: Lauren Adkins

Institutions: University of Southern California, City Of Hope National Medical Center, City of Hope, USC Norris Comprehensive Cancer Center

Observed institutions: University of Southern California, City Of Hope National Medical Center, University of Florida Health, Moffitt Cancer Center, University of Florida, City of Hope, USC Norris Comprehensive Cancer Center

OpenAlex ID: A5008096883

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial

2024 · Tanya B. Dorff, M. Suzette Blanchard, et al. · Nature Medicine · 139

Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting

2023 · Eric Hee Jun Lee, John P. Murad, et al. · Nature Communications · 114

Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery

2025 · John P. Murad, Lea Christian, et al. · Nature Biomedical Engineering · 46

Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC).

2022 · Tanya B. Dorff, Suzette Blanchard, et al. · Journal of Clinical Oncology · 19

Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).

2023 · Tanya B. Dorff, Suzette Blanchard, et al. · Journal of Clinical Oncology · 10

A phase I study to evaluate PSCA-targeting chimeric antigen receptor (CAR)-T cells for patients with PSCA+ metastatic castration-resistant prostate cancer (mCRPC).

2020 · Tanya B. Dorff, Suzette Blanchard, et al. · Journal of Clinical Oncology · 9

A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer.

2024 · Peter D. Zang, Suzette Blanchard, et al. · Journal of Clinical Oncology · 4

Toxicity reporting consistency and subjective minimizing language use in colorectal cancer (CRC) and pancreatic cancer (PaC) clinical trials: A systematic review of phase III randomized controlled trials (RCTs) presented at ASCO between 2012-2022.

2023 · James Yu, Turab J Mohammed, et al. · Journal of Clinical Oncology · 3

Ctim-07. a Phase 1 Study of Intraventricularly Administered Autologous Her2-targeting Chimeric Antigen Receptor T Cells (her2-car T Cells), With and Without Lymphodepletion, in Her2-positive Breast Cancer Patients With Recurrent Brain And/or Leptomeningeal Metastases

2025 · Jana Portnow, Suzette Blanchard, et al. · Neuro-Oncology · 2

Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery

2025 · John P. Murad, Lea Christian, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Abstract 4791: Characterizing interventions to reduce disparities in lung-cancer screening uptake by state Medicaid expansion status: A scoping review

2024 · Miranda J. Reid, Caretia Washington, et al. · Cancer Research

Abstract IA019: Tumor microenvironment modulation is critical for cellular immunotherapy efficacy

2023 · Tanya B Dorff, M Suzette Blanchard, et al. · Cancer Research

Works count: 12

Citation count: 346

H-index: 6

I10-index: 5